CK-0801 is under clinical development by Cellenkos and currently in Phase I for Aplastic Anemia. According to GlobalData, Phase I drugs for Aplastic Anemia have a 69% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CK-0801’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CK-0801 overview

CK-0801 is under development for the treatment of inflammatory disorders and bone marrow failure syndrome including aplastic anemia, myelodysplastic syndrome and myelofibrosis. It is administered through intravenous route. The drug candidate comprises umbilical cord blood derived T-regulatory cells. It was under development for Guillain-Barre syndrome.

Cellenkos overview

Cellenkos is an early-stage clinical biotechnology company, which focuses on the development of umbilical cord blood-derived T-regulatory cellular therapies for the treatment of autoimmune diseases and inflammatory disorders. The infusion of its lead product candidate, CK0801, leads to the replacement of defective T-REGs and protection of the body from T cell attacks with restoration of immune homeostasis. Cellenkos works in collaboration with the University of Texas MD Anderson Cancer Center to treat a wide range of autoimmune diseases including multiple sclerosis, lupus, rheumatoid arthritis and inflammatory disorders such as Crohn’s disease and aplastic anemia. The company is funded by Golden Meditech Holdings Limited to expand the T-REG technologies. Cellenkos is headquartered in Houston, Texas, the US.

For a complete picture of CK-0801’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.